Dr. Sangeeta Bhatia, biomedical engineer and professor at MIT, is the recipient of the 2014 $500,000 Lemelson-MIT Prize. Bhatia is recognized for designing and commercializing miniaturized technologies with applications to improve human health.
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced pre-clinical data presented on Sunday, September 7, 2014, at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
PharmAthene, Inc. and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market.
The newly merged SUNY College of Nanoscale Science and Engineering (CNSE)/SUNY Institute of Technology (SUNYIT) institution today announced the National Institute of Environmental Health Sciences has awarded a $1.65 million grant to further research conducted by nanobioscience professor Dr. Thomas Begley that identifies signals which cancer cells use to respond to their environment.
The potential for deployment of cold plasma sources in medical and biological applications continues to increase in areas such as dentistry, surgery, wound sterilisation and general surface decontamination. Successful optimisation of these gas-phase cold plasmas requires detailed characterisation and quantification of the plasma beam to establish the actual abundances of the reactive species within the feed-gas and the variances with feed-gas composition.
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate (RSV F vaccine) bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab (Syangis®) at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC.
Individuals who are squeamish about injections or are looking for a way to let collagen penetrate deeper into the skin may soon have a solution that is faster, more effective and painless. The key lies in a small adhesive patch topped with minuscule needles that is pioneered by researchers from the National University of Singapore (NUS).
Ascendia Pharmaceuticals, a start-up specialty pharmaceutical company in the business of providing formulation technologies and product development services for poorly soluble molecules, today announced that the company has successfully applied its nano-emulsion technology platform to a novel injectable formulation of clopidogrel - the world’s top-selling blood thinner medicine. Ascendia has advanced the program to pre-IND development stage, and has filed US and worldwide PCT patent applications on the product.
Researchers at Guangdong Medical College have discovered that the combination of serum surface-enhanced Raman scattering (SERS) spectroscopy and support vector machine (SVM) diagnostic algorithm demonstrated great potential for non-invasive screening of prostate cancer. Screening for cancer can help prevent related deaths. Many methods exist, but there is a growing need for more effective, safe and cost-effective methods.
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will present data from recent preclinical studies of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Nanoparticle Vaccine) at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., September 5-9, 2014 at the Walter E. Washington Convention Center.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.